Cochlear Future Growth

Future criteria checks 3/6

Cochlear is forecast to grow earnings and revenue by 11.7% and 8.1% per annum respectively. EPS is expected to grow by 11.7% per annum. Return on equity is forecast to be 25% in 3 years.

Key information

11.7%

Earnings growth rate

11.7%

EPS growth rate

Medical Equipment earnings growth	16.3%
Revenue growth rate	8.1%
Future return on equity	25.0%
Analyst coverage	Good
Last updated	12 Dec 2024

Recent future growth updates

Cochlear Limited Just Missed EPS By 7.4%: Here's What Analysts Think Will Happen Next

Aug 16

Recent updates

Some Investors May Be Worried About Cochlear's (ASX:COH) Returns On Capital

Nov 19

Is Cochlear Limited (ASX:COH) Expensive For A Reason? A Look At Its Intrinsic Value

Nov 04

We Think Shareholders May Consider Being More Generous With Cochlear Limited's (ASX:COH) CEO Compensation Package

Oct 18

Cochlear Limited's (ASX:COH) Shareholders Might Be Looking For Exit

Sep 19

Cochlear Limited Just Missed EPS By 7.4%: Here's What Analysts Think Will Happen Next

Aug 16

Earnings and Revenue Growth Forecasts

ASX:COH - Analysts future estimates and past financials data (AUD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2027	2,924	532	480	600	13
6/30/2026	2,679	468	403	521	14
6/30/2025	2,464	422	401	522	14
6/30/2024	2,236	357	299	389	N/A
3/31/2024	2,193	354	317	410	N/A
12/31/2023	2,149	350	335	430	N/A
9/30/2023	2,043	326	301	396	N/A
6/30/2023	1,936	301	267	362	N/A
3/31/2023	1,824	281	263	352	N/A
12/31/2022	1,713	261	259	341	N/A
9/30/2022	1,681	275	279	359	N/A
6/30/2022	1,648	289	299	377	N/A
3/31/2022	1,612	273	266	340	N/A
12/31/2021	1,575	257	233	304	N/A
9/30/2021	1,536	291	216	285	N/A
6/30/2021	1,498	324	199	265	N/A
3/31/2021	1,403	82	-52	34	N/A
12/31/2020	1,308	-160	-302	-198	N/A
9/30/2020	1,314	-199	-295	-178	N/A
6/30/2020	1,321	-238	-288	-158	N/A
3/31/2020	1,400	34	-80	50	N/A
12/31/2019	1,479	306	128	259	N/A
9/30/2019	1,453	291	155	277	N/A
6/30/2019	1,427	277	181	296	N/A
3/31/2019	1,422	270	217	313	N/A
12/31/2018	1,418	264	252	330	N/A
9/30/2018	1,391	255	230	294	N/A
6/30/2018	1,364	246	208	258	N/A
3/31/2018	1,329	234	N/A	254	N/A
12/31/2017	1,294	223	N/A	250	N/A
9/30/2017	1,274	223	N/A	255	N/A
6/30/2017	1,254	224	N/A	260	N/A
3/31/2017	1,218	215	N/A	237	N/A
12/31/2016	1,182	206	N/A	214	N/A
9/30/2016	1,156	198	N/A	199	N/A
6/30/2016	1,131	189	N/A	185	N/A
3/31/2016	1,088	179	N/A	179	N/A
12/31/2015	1,045	168	N/A	172	N/A
9/30/2015	986	157	N/A	181	N/A
6/30/2015	926	146	N/A	189	N/A
3/31/2015	899	145	N/A	178	N/A
12/31/2014	872	144	N/A	168	N/A
9/30/2014	839	119	N/A	140	N/A
6/30/2014	805	94	N/A	111	N/A
3/31/2014	769	85	N/A	93	N/A
12/31/2013	732	76	N/A	75	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: COH's forecast earnings growth (11.7% per year) is above the savings rate (2.6%).

Earnings vs Market: COH's earnings (11.7% per year) are forecast to grow slower than the Australian market (12.5% per year).

High Growth Earnings: COH's earnings are forecast to grow, but not significantly.

Revenue vs Market: COH's revenue (8.1% per year) is forecast to grow faster than the Australian market (5.8% per year).

High Growth Revenue: COH's revenue (8.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: COH's Return on Equity is forecast to be high in 3 years time (25%)

Cochlear Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Cochlear Limited Just Missed EPS By 7.4%: Here's What Analysts Think Will Happen Next

Price target increased by 7.0% to AU$272

Cochlear Limited Provides Earnings Outlook for the Year 2023

Cochlear Limited Provides Earnings Guidance for the Fiscal Year 2022

Recent updates

Some Investors May Be Worried About Cochlear's (ASX:COH) Returns On Capital

CEO, MD exercised options and sold AU$3.1m worth of stock

Is Cochlear Limited (ASX:COH) Expensive For A Reason? A Look At Its Intrinsic Value

We Think Shareholders May Consider Being More Generous With Cochlear Limited's (ASX:COH) CEO Compensation Package

Now 20% overvalued

Cochlear Limited's (ASX:COH) Shareholders Might Be Looking For Exit

CEO, MD exercised options and sold AU$613k worth of stock

Stu Sayers to Appoint as President, Asia Pacific & Latin America of Cochlear Limited, Effective from 1 January 2025

Upcoming dividend of AU$2.10 per share

Final dividend of AU$2.10 announced

Cochlear Limited Announces Ordinary Dividend for the Period of Six Months Ended June 30, 2024, Payable on October 10, 2024

Cochlear Limited Just Missed EPS By 7.4%: Here's What Analysts Think Will Happen Next

Full year 2024 earnings: EPS misses analyst expectations

Cochlear Limited (ASX:COH) announces an Equity Buyback for AUD 75 million worth of its shares.

Investors Could Be Concerned With Cochlear's (ASX:COH) Returns On Capital

Cochlear Limited Appoints Caroline Clarke as Non-Executive Director, Effective from 2 September 2024

Cochlear Limited Announces Executive Changes

Here's Why We Think Cochlear (ASX:COH) Is Well Worth Watching

Cochlear Limited (ASX:COH) acquired Oticon Medical A/s from Demant A/S (CPSE:DEMANT).

Cochlear Limited Announces Company Secretary Changes

Cochlear Limited Receives Fda Clearance to Lower the Age for the Osia System to 5-Year-Old

Cochlear (ASX:COH) Might Be Having Difficulty Using Its Capital Effectively

Upcoming dividend of AU$2.00 per share

First half dividend increased to AU$2.00

Here's Why We Think Cochlear (ASX:COH) Is Well Worth Watching

First half 2024 earnings: EPS in line with expectations, revenues disappoint

Price target increased by 7.0% to AU$272

Cochlear (ASX:COH) Might Be Having Difficulty Using Its Capital Effectively

Upcoming dividend of AU$1.75 per share at 1.2% yield

Cochlear Limited Introduces Next Generation Cochlear Osia System with Ability to Have MRI at 3.0 T

Cochlear Limited to Report Fiscal Year 2024 Results on Aug 15, 2024

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Cochlear Limited Announces Andrew Denver, Non-Executive Director Intention to Retire At AGM to Be Held on 17 October 2023

Upcoming dividend of AU$1.55 per share at 1.3% yield

Cochlear Limited Provides Earnings Outlook for the Year 2023

Cochlear Limited (ASX:COH) announces an Equity Buyback for AUD 75 million worth of its shares.

Cochlear Limited, Annual General Meeting, Oct 17, 2023

FDA Approves Cochlear Limited's Nucleus 8 Sound Processor, Smaller, Smarter, Better Connected Cochlear Implant Technology

Key Executive recently bought AU$97k worth of stock

Upcoming dividend of AU$1.45 per share

Full year 2022 earnings: EPS misses analyst expectations

Cochlear Announces Final Dividend Payable on 17 October 2022

Cochlear Limited Appoints Karen Penrose to Board, Effective on 1 July 2022

Cochlear Limited, Annual General Meeting, Oct 18, 2022

Cochlear Limited to Report First Half, 2023 Results on Feb 15, 2023

Upcoming dividend of AU$1.55 per share

Investor sentiment improved over the past week

First half 2022 earnings: EPS and revenues exceed analyst expectations

Cochlear Limited Announces Interim Dividend Expected to Be Payable on 21 April 2022

FDA Approves Cochlear Nucleus Implants for Unilateral Hearing Loss/Single-Sided Deafness

Independent Non-Executive Director recently bought AU$56k worth of stock

Cochlear Limited Advises of US Patent Infringement Complaint

Upcoming dividend of AU$1.40 per share

CEO, MD exercised options and sold AU$295k worth of stock

Sensorion and Cochlear to Begin First Clinical Trial of SENS-401 for Hearing Preservation in Combination with Cochlear Implantation

Independent Non-Executive Director recently bought AU$94k worth of stock

Independent Chairman Roderic Holliday-Smith has left the company

Independent Chairman Roderic Holliday-Smith has left the company

Full year 2021 earnings released: EPS AU$4.97 (vs AU$4.00 loss in FY 2020)

Cochlear Limited Provides Earnings Guidance for the Fiscal Year 2022

Non-Executive Independent Director Abbas Hussain has left the company

New Cochlear CoPilot app to help adults improve hearing outcomes through skills training

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies